Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for severe immune-mediated inflammation.
Bionyra has raised $165.0M in total funding. The most recent round was Series A. The last funding was announced in June 2026.
Bionyra's investors include Sofinnova Partners, Sanofi Ventures, Jeito Capital, Arkin Capital, Apollo Health Ventures.
Bionyra is headquartered in Paris, France.
Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for severe immune-mediated inflammation.
Bionyra is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bionyra — Funding & Investors." VCBacked, June 22, 2026, https://www.vcbacked.co/company/bionyra. Accessed July 20, 2026.
VCBacked. (2026). Bionyra — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/bionyra
{{cite web |title=Bionyra — Funding & Investors |url=https://www.vcbacked.co/company/bionyra |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated